insider trading  trv gp iii llc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  trv gp iii llc select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm global blood therapeutics inc gbt third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llcthird rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert istarr kevin p owner    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing other  pm nana voyager therapeutics inc vygr third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llcstarr kevin ptepper robert i owner   direct view other  pm nana editas medicine inc edit third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jstarr kevin ptepper robert i owner   direct view conversion  pm nana editas medicine inc edit third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jstarr kevin ptepper robert i owner   direct view conversion  pm nana editas medicine inc edit third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jstarr kevin ptepper robert i owner   direct view conversion  pm nana editas medicine inc edit third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jstarr kevin ptepper robert i owner   direct view conversion  pm nana editas medicine inc edit third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jstarr kevin ptepper robert i owner   direct view conversion  pm nana voyager therapeutics inc vygr third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llcstarr kevin ptepper robert i owner   direct view conversion  pm nana voyager therapeutics inc vygr third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llcstarr kevin ptepper robert i owner   direct view conversion  pm nana myokardia inc myok third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llcthird rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view conversion  pm nana myokardia inc myok third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llcthird rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view conversion  pm nana myokardia inc myok third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llcthird rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view conversion  pm nana myokardia inc myok third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llcthird rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view conversion  pm nana global blood therapeutics inc gbt third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view conversion  pm nana global blood therapeutics inc gbt third rock ventures iii lpthird rock ventures gp iii lptrv gp iii llclevin mark jtepper robert i owner   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  sage insider trading  sage therapeutics inc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  sage therapeutics inc sage select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in goto page   next common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm sage therapeutics inc sage anderson thomassee remarks    direct view sale  pm sage therapeutics inc sage iguchi kimicfo secretary and treasurer    direct view sale  pm sage therapeutics inc sage iguchi kimicfo secretary and treasurer    direct view sale  am sage therapeutics inc sage iguchi kimicfo secretary and treasurer    direct view sale  pm sage therapeutics inc sage robichaud albertchief scientific officer    direct view sale  pm sage therapeutics inc sage iguchi kimicfo secretary and treasurer    direct view sale  pm sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner    direct view sale  pm sage therapeutics inc sage starr kevin pdirector owner    directindirect view sale  pm sage therapeutics inc sage kanes stephenchief medical officer    direct view sale  pm sage therapeutics inc sage robichaud albertchief scientific officer    direct view purchase  pm sage therapeutics inc sage iguchi kimicfo secretary and treasurer    direct view purchase  pm sage therapeutics inc sage jonas jeffrey msee remarksdirector    direct view sale  pm sage therapeutics inc sage kanes stephenchief medical officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana sage therapeutics inc sage anderson thomassee remarks   direct view tax withholding  pm nana sage therapeutics inc sage anderson thomassee remarks   direct view exercise  pm na sage therapeutics inc sage anderson thomassee remarks   direct view option award  pm  sage therapeutics inc sage cook anne mariegeneral counsel   direct view option award  pm  sage therapeutics inc sage anderson thomassee remarks   direct view option award  pm  sage therapeutics inc sage iguchi kimicfo secretary and treasurer   direct view option award  pm  sage therapeutics inc sage jonas jeffrey msee remarksdirector   direct view option award  pm  sage therapeutics inc sage kanes stephenchief medical officer   direct view gift  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view gift  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view gift  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view gift  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view gift  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view option award  pm  sage therapeutics inc sage robichaud albertchief scientific officer   direct view exercise  pm nana sage therapeutics inc sage anderson thomassee remarks   direct view exercise  pm na sage therapeutics inc sage anderson thomassee remarks   direct view exercise  pm nana sage therapeutics inc sage robichaud albertchief scientific officer   direct view exercise  pm na sage therapeutics inc sage robichaud albertchief scientific officer   direct view other  pm nana sage therapeutics inc sage starr kevin pdirector owner   indirect view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view option award  pm na sage therapeutics inc sage germano geno jdirector   direct view option award  am na sage therapeutics inc sage paul steven mdirector   direct view option award  am na sage therapeutics inc sage pien howard hdirector   direct view option award  am na sage therapeutics inc sage frates james mdirector   direct view option award  am na sage therapeutics inc sage starr kevin pdirector owner   direct view option award  am na sage therapeutics inc sage cola michael fdirector   direct view exercise  pm nana sage therapeutics inc sage kanes stephenchief medical officer   direct view exercise  pm na sage therapeutics inc sage kanes stephenchief medical officer   direct view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view gift  pm nana sage therapeutics inc sage paul steven mdirector   indirect view option award  pm na sage therapeutics inc sage jonas jeffrey msee remarksdirector   direct view option award  pm na sage therapeutics inc sage robichaud albertchief scientific officer   direct view option award  pm na sage therapeutics inc sage kanes stephenchief medical officer   direct view option award  pm na sage therapeutics inc sage iguchi kimicfo secretary and treasurer   direct view option award  pm na sage therapeutics inc sage cook anne mariegeneral counsel   direct view option award  pm na sage therapeutics inc sage anderson thomassee remarks   direct view exercise  pm nana sage therapeutics inc sage iguchi kimicfo secretary and treasurer   direct view exercise  pm na sage therapeutics inc sage iguchi kimicfo secretary and treasurer   direct view exercise  pm nana sage therapeutics inc sage jonas jeffrey msee remarksdirector   direct view exercise  pm na sage therapeutics inc sage jonas jeffrey msee remarksdirector   direct view other  pm nana sage therapeutics inc sage starr kevin pdirector owner   indirect view other  pm nana sage therapeutics inc sage starr kevin pdirector owner   indirect view other  pm nana sage therapeutics inc sage starr kevin pdirector owner   indirect view other  pm nana sage therapeutics inc sage starr kevin pdirector owner   direct view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view other  pm nana sage therapeutics inc sage third rock ventures ii lpthird rock ventures gp ii lptrv gp ii llclevin mark jtepper robert i owner   direct view other  am nana sage therapeutics inc sage nelsen robertdirector   indirect view other  am nana sage therapeutics inc sage nelsen robertdirector   direct view exercise  pm nana sage therapeutics inc sage kanes stephenchief medical officer   direct view exercise  pm na sage therapeutics inc sage kanes stephenchief medical officer   direct view other  pm nana sage therapeutics inc sage nelsen robertdirector   indirect view other  pm nana sage therapeutics inc sage nelsen robertdirector   direct view goto page   next   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  prospectus filed pursuant to rule b b july edition of canna investorshub magazine now available support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed quotechartlevel tradesnewsfinancialshistoricaltechnical analysismessage boardmyokardia inc mm nasdaq prospectus filed pursuant to rule b b date    pm source  edgar us regulatory stock  myokardia inc mm myok quote       pm prospectus filed pursuant to rule b btweet print table of contents filed pursuant to rule b registration no  prospectus    shares of common stock     this prospectus relates to the proposed resale or other disposition of up to  shares of myokardia inc common stock par value  per share by the selling stockholders identified in this prospectus all of the shares are outstanding shares of common stock held by the selling stockholders we are not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of common stock by the selling stockholders the selling stockholders or their pledgees assignees or successorsininterest may offer and sell or otherwise dispose of the shares of common stock described in this prospectus from time to time the selling stockholders will bear all commissions and discounts if any attributable to the sales of shares we will bear all other costs expenses and fees in connection with the registration of the shares see plan of distribution beginning on page  for more information about how the selling stockholders may sell or dispose of their shares of common stock our common stock is traded on the nasdaq global select market under the symbol myok on july   the last reported sale price for our common stock on the nasdaq global select market was  per share     investing in our common stock involves a high degree of risk before making an investment decision please read the information under the heading  risk factors  beginning on page  of this prospectus and in the documents incorporated by reference into this prospectus neither the securities and exchange commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus any representation to the contrary is a criminal offense     the date of this prospectus is july   table of contents table of contents        page   about myokardia         risk factors         special note regarding forwardlooking statements         use of proceeds         selling stockholders         plan of distribution         validity of the securities         experts         where you can find more information         incorporation by reference         about this prospectus this prospectus and the documents incorporated by reference into it are part of a registration statement that we filed with the securities and exchange commission the sec utilizing a shelf registration process under this shelf registration process certain selling stockholders may from time to time sell the shares of common stock described in this prospectus in one or more offerings we have not authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in this prospectus you must not rely upon any information or representation not contained or incorporated by reference in this prospectus the selling stockholders are offering to sell and seeking offers to buy shares of our common stock only in jurisdictions where it is lawful to do so this prospectus does not constitute an offer to sell or the solicitation of an offer to buy any shares other than the registered shares to which they relate nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy shares in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction you should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference even though this prospectus is delivered or shares are sold on a later date table of contents about myokardia we are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases our initial focus is on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction we have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathyhypertrophic cardiomyopathy or hcm and dilated cardiomyopathy or dcm myk our lead product candidate for the treatment of hcm is currently in phase  clinical development we intend to advance our second product candidate myk for the treatment of dcm into phase  clinical development by the first half of  applying our precision development strategy we have demonstrated clinical proof of mechanism for myk in both healthy volunteers and in hcm patients we intend to pursue a similar clinical approach for myk in  myk was granted orphan drug designation by the us food and drug administration or the fda for the treatment of symptomatic obstructive hcm we have never been profitable and have incurred net losses in each year since inception our net losses were  million and  million for the three months ended march  and  respectively as of march   we had an accumulated deficit of  million to date we have not generated any product revenue we do not expect to receive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations as of march   we had  million of cash and cash equivalents we were incorporated in delaware in june  our principal executive offices are located at  allerton ave south san francisco california  our telephone number is   and our email address is infomyokardiacom our internet website address is wwwmyokardiacom  no portion of our website is incorporated by reference into this prospectus we do not incorporate the information on or accessible through our website into this prospectus and you should not consider any information on or that can be accessed through our website as part of this prospectus our common stock trades on the nasdaq global select market under the symbol myok we are an emerging growth company as defined in the jumpstart our business startups act of  we will remain an emerging growth company until the earlier of  the last day of the fiscal year a following the fifth anniversary of the completion of our initial public offering b in which we have total annual gross revenue of at least  billion or c in which we are deemed to be a large accelerated filer which means the market value of our common stock that is held by nonaffiliates exceeds  million as of the prior june th and  the date on which we have issued more than  billion in nonconvertible debt during the prior threeyear period we use various trademarks and trade names in our business including without limitation our corporate name and logo all other trademarks or trade names referred to in this prospectus are the property of their respective owners solely for convenience the trademarks and trade names in this prospectus may be referred to without the ® and  symbols but such references should not be construed as any indicator that their respective owners will not assert to the fullest extent under applicable law their rights thereto    table of contents risk factors investment in any securities offered pursuant to this prospectus involves risks you should carefully consider the risk factors incorporated by reference to our most recent annual report on form k quarterly reports on form q or current reports on form k we file after the date of this prospectus and all other information contained or incorporated by reference into this prospectus as updated by our subsequent filings under the securities exchange act of  as amended the exchange act and the risk factors and other information contained in the applicable prospectus supplement before acquiring any of such securities the occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities    table of contents special note regarding forwardlooking statements this prospectus including the documents incorporated by reference herein and therein contains forwardlooking statements within the meaning of section a of the securities act of  as amended the securities act and section e of the exchange act we have based these forwardlooking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business forwardlooking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at or by which such performance or results will be achieved forwardlooking statements are based on information available at the time those statements are made andor managements good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forwardlooking statements forwardlooking statements include all statements that are not historical facts in some cases you can identify forwardlooking statements by terms such as may might will objective intend should could can would expect believe anticipate project target design estimate predict potential plan or the negative of these terms and similar expressions intended to identify forwardlooking statements and similar expressions and comparable terminology intended to identify forwardlooking statements these statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties including those set forth below in the sections entitled risk factors in our most recent annual report on form k quarterly reports on form q or current reports on form k we file after the date of this prospectus forwardlooking statements include but are not limited to statements about        the timing and success of our ongoing phase  pioneerhcm study of myk in symptomatic obstructive hcm patients and phase  clinical trial of myk in healthy volunteers        the timing of and our ability to initiate an additional phase  clinical trial of myk in symptomatic nonobstructive hcm patients        our ability to enroll patients in our clinical trials at the pace that we project        our ability to obtain regulatory approval for any of our product candidates without the need for large outcomebased studies        our ability to identify and advance through clinical development any additional product candidates from our precision medicine platform including from our hcm dcm and lus programs        our ability to successfully maintain our strategic collaboration with sanofi        our ability to obtain and maintain intellectual property protection for our precision medicine platform and our product candidates        our ability to successfully build a specialty sales force and commercial infrastructure to market myk and any product candidates from our programs if approved in the united states and any product candidates for our other programs worldwide        our ability to compete with companies currently producing or engaged in the clinical development of treatments for the disease indications that we pursue        our reliance on third parties to conduct our clinical trials and to manufacture drug substance for use in our clinical trials        our ability to retain and recruit key personnel        our expectations regarding government and thirdparty payor coverage and reimbursement        our estimates of our expenses ongoing losses future revenue capital requirements and our needs for or ability to obtain additional financing        our expectations regarding the time during which we will be an emerging growth company under the jobs act    table of contents      our financial performance and        developments and projections relating to our competitors or our industry given these uncertainties you should not place undue reliance on these forwardlooking statements these forwardlooking statements represent our estimates and assumptions only as of the date of this prospectus and the documents incorporated by reference herein regardless of the time of delivery of this prospectus or any sale of our common stock and except as required by law we undertake no obligation to update or revise publicly any forwardlooking statements whether as a result of new information future events or otherwise after the date of prospectus we qualify all of our forwardlooking statements by these cautionary statements use of proceeds we will not receive any of the proceeds from the sale of shares of our common stock in this offering the selling stockholders will receive all of the proceeds from this offering the selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage accounting tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares we will bear all other costs fees and expenses incurred in effecting the registration of the shares covered by this prospectus including without limitation all registration and filing fees fees and expenses of our counsel certain expenses of counsel to the selling stockholders and our independent registered public accountants selling stockholders on april   we entered into a second amended and restated investors rights agreement as amended by that certain amendment no  to second amended and restated investors rights agreement dated april   with the selling stockholders and certain other stockholders the ira this prospectus covers the sale or other disposition by the selling stockholders of up to the total number of shares of common stock held by the selling stockholders subject to the ira the selling stockholders acquired such shares of common stock pursuant to stock purchase agreements entered into from time to time in connection with the issuance and sale of our common stock and convertible preferred stock prior to our initial public offering which resulted in all of the outstanding shares of our convertible preferred stock being converted into shares of common stock throughout this prospectus when we refer to the shares of our common stock being registered on behalf of the selling stockholders we are referring to the shares held by the selling stockholders subject to the ira and when we refer to the selling stockholders in this prospectus we are referring to the selling stockholders as investors under the ira we are registering the abovereferenced shares to permit each of the selling stockholders to resell or otherwise dispose of the shares in the manner contemplated under plan of distribution below except as otherwise disclosed in the footnotes below none of the selling stockholders has or within the past three years has had any position office or other material relationship with us the following table sets forth the name of each selling stockholder the number of shares owned by each of the respective selling stockholders the number of shares that may be offered under this prospectus and the number of shares of our common stock owned by the selling stockholders assuming all of the shares covered hereby are sold the number of shares in the column number of shares being offered represents all of the shares that a selling stockholder may offer under this prospectus the selling stockholders may sell some all or none of their shares we do not know how long the selling stockholders will hold the shares before selling them and we currently have no agreements arrangements or understandings with the selling stockholders regarding the sale or other disposition of any of the shares the shares covered hereby may be offered from time to time by the selling stockholders    table of contents the information set forth below is based upon information obtained from the selling stockholders and upon information in our possession regarding the issuance of shares of common stock to the selling stockholders in connection with the private placement transaction the percentages of shares owned after the offering are based on  shares of our common stock outstanding as of june   including the shares of common stock covered hereby   name of selling stockholders    shares of common stock beneficially owned prior to offering      number of shares being offered      shares of common stock beneficially owned after offering            number      percent   entities affiliated with third rock ventures                                        beneficial ownership is a term broadly defined by the sec in rule d under the exchange act and includes more than the typical form of stock ownership that is stock held in the persons name the term also includes what is referred to as indirect ownership meaning ownership of shares as to which a person has or shares investment power for purposes of this table a person or group of persons is deemed to have beneficial ownership of any shares underlying options and other purchase rights that are currently exercisable or exercisable within  days of june      assumes that all shares being registered in this prospectus are resold to third parties and that with respect to a particular selling stockholder such selling stockholder sells all shares of common stock registered under this prospectus held by such selling stockholder    consists of i  shares of common stock directly owned by third rock ventures ii lp trv ii ii  shares of common stock directly owned by third rock ventures iii lp trv iii each of third rock ventures gp ii lp trv gp ii the sole general partner of trv ii and trv gp ii llc trv gp ii llc the sole general partner of trv gp ii and mark levin kevin p starr and robert i tepper the managing members of trv gp ii llc may be deemed to have voting and investment power over the shares held of record by trv ii and each of third rock ventures gp iii lp trv gp iii the sole general partner of trv iii and trv gp iii llc trv gp iii llc the sole general partner of trv gp iii and mark levin kevin p starr and robert i tepper the managing managers of trv gp iii llc may be deemed to have voting and investment power over the shares held of record by trv iii kevin p starr is a member of our board of directors and has served in such capacity since june  the address of each of trv ii and trv iii is  newbury street rd floor boston massachusetts     table of contents plan of distribution the selling stockholders may sell the shares of common stock from time to time pursuant to underwritten public offerings negotiated transactions block trades or a combination of these methods or through underwriters or dealers through agents andor directly to one or more purchasers the shares of common stock may be distributed from time to time in one or more transactions        at a fixed price or prices which may be changed        at market prices prevailing at the time of sale        at prices related to such prevailing market prices or        at negotiated prices the selling stockholders may also sell shares under rule  under the securities act if available or section a under the securities act rather than under this prospectus provided that they meet the criteria and conform to the requirements of those provisions if the selling stockholders effect such transactions by selling shares of common stock to or through underwriters brokerdealers or agents such underwriters brokerdealers or agents engaged by the selling stockholders may arrange for other brokerdealers to participate in sales brokerdealers may receive commissions or discounts from the selling stockholders or if any brokerdealer acts as agent for the purchaser of shares from the purchaser in amounts to be negotiated the selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved the selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and if they default in the performance of their secured obligations the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus or under a supplement or amendment to this prospectus under rule b or other applicable provision of the securities act amending if necessary the list of selling stockholders to include the pledgee transferee or other successors in interest as selling stockholders under this prospectus each selling stockholder has informed us that it is not a registered brokerdealer and does not have any written or oral agreement or understanding directly or indirectly with any person to distribute the common stock if we are notified in writing by a selling stockholder that any material arrangement has been entered into with a brokerdealer for the sale of common stock through a block trade special offering exchange distribution or secondary distribution or a purchase by a broker or dealer we will file a supplement to this prospectus if required pursuant to rule b under the securities act disclosing i the name of each such selling stockholder and of the participating brokerdealers ii the number of shares involved iii the price at which such shares of common stock were sold iv the commissions paid or discounts or concessions allowed to such brokerdealers where applicable v that such brokerdealers did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus and vi other facts material to the transaction in addition upon being notified in writing by a selling stockholder who is an affiliate that a donee or pledge intends to sell more than  shares or  worth of common stock we will file a supplement to this prospectus if then required in accordance with applicable securities law the selling stockholders also may transfer the shares of common stock in other circumstances in which case the transferees pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus in connection with the sale of the shares of common stock or interests in shares of common stock the selling stockholders may enter into hedging transactions after the effective date of the registration statement of which this prospectus is a part with brokerdealers or other financial institutions which may in turn engage in short sales of the common stock in the course of hedging the positions they assume the selling stockholders may also sell shares of common stock short after the effective date of the registration statement of which this prospectus is a part and deliver these securities to close out their short positions or loan or pledge the common stock to brokerdealers that    table of contents in turn may sell these securities the selling stockholders may also enter into option or other transactions after the effective date of the registration statement of which this prospectus is a part with brokerdealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such brokerdealer or other financial institution of shares offered by this prospectus which shares such brokerdealer or other financial institution may resell pursuant to this prospectus as supplemented or amended to reflect such transaction the selling stockholders and any brokerdealers or agents that are involved in selling the shares may be deemed to be underwriters within the meaning of the securities act in connection with such sales in such event any commissions received by such brokerdealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the securities act the maximum commission or discount to be received by any member of the financial industry regulatory authority finra or independent brokerdealer will not be greater than eight percent of the initial gross proceeds from the sale of any security being sold we have advised the selling stockholders that they are required to comply with regulation m promulgated under the exchange act during such time as they may be engaged in a distribution of the shares the foregoing may affect the marketability of the common stock the aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions if any each of the selling stockholders reserves the right to accept and together with their agents from time to time to reject in whole or in part any proposed purchase of common stock to be made directly or through agents we will not receive any of the proceeds from this offering we are required to pay all fees and expenses incident to the registration of the shares we have agreed to indemnify the selling stockholders against certain losses damages and liabilities including liabilities under the securities act the exchange act or otherwise we have agreed with the selling stockholders to use our commercially reasonable efforts to keep the registration statement of which this prospectus constitutes a part effective for a period of up to one hundred twenty days or if earlier until the distribution contemplated in the registration statement has been completed validity of the securities certain legal matters in connection with this offering will be passed upon for us by goodwin procter llp san francisco california additional legal matters may be passed upon for us the selling stockholders or any underwriters dealers or agents by counsel that we will name in the applicable prospectus supplement experts the financial statements incorporated in this prospectus by reference to the annual report on form k for the year ended december   have been so incorporated in reliance on the report of pricewaterhousecoopers llp an independent registered public accounting firm given on the authority of said firm as experts in auditing and accounting where you can find more information we file annual quarterly and current reports proxy statements and other information with the sec you may read and copy these reports proxy statements and other information at the secs public reference room at  f street ne washington dc  please call the sec at sec for more information about the operation of the public reference room you can request copies of these documents by writing to the sec and paying a fee for the copying costs our sec filings are also available at the secs website at wwwsecgov in addition we maintain    table of contents a website that contains information about us at wwwmyokardiacom the information found on or otherwise accessible through our website is not incorporated into and does not form a part of this prospectus or any other report or document we file with or furnish to the sec this prospectus is part of a registration statement that we filed with the sec the registration statement contains more information than this prospectus regarding us and our common stock including certain exhibits and schedules with respect to the statements contained in this prospectus regarding the contents of any agreement or any other document in each instance the statement is qualified in all respects by the complete text of the agreement or document a copy of which has been filed as an exhibit to the registration statement you can obtain a copy of the registration statement from the sec at the address listed above or from the secs website incorporation by reference the sec allows us to incorporate by reference the information we file with them which means that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus the information incorporated by reference is considered to be part of this prospectus and later information that we file with the sec will automatically update and supersede this information we incorporate by reference the documents listed below and any future information filed rather than furnished with the sec under sections a c  or d of the exchange act between the date of this prospectus and the termination of this offering provided however that we are not incorporating any information furnished under item  or item  of any current report on form k        annual report on form k for the year ended december   filed with the sec on march          the information specifically incorporated by reference into our annual report on form k for the year ended december   from our definitive proxy statement on schedule a other than information furnished rather than filed which was filed with the sec on april          quarterly report on form q filed with the sec for the quarter ended march   filed with the sec on may          current reports on form k filed with the sec on january   as to item  only february   as to item  only march   as to item  only april   as to item  only and june   and        the description of our common stock contained in our registration statement on form a filed with the sec on october   under section b of the exchange act including any amendments or reports filed for the purpose of updating such description upon request we will provide without charge to each person including any beneficial owner to whom a copy of this prospectus is delivered a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus you may request a copy of these filings and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus at no cost by writing or telephoning us at the following address  allerton ave south san francisco ca  telephone   you may also access these documents free of charge on the secs website at wwwsecgov or on our website at wwwmyokardiacom  information contained on our website is not incorporated by reference into this prospectus and you should not consider any information on or that can be accessed from our website as part of this prospectus or any accompanying prospectus supplement this prospectus is part of a registration statement we filed with the sec we have incorporated exhibits into this registration statement you should read the exhibits carefully for provisions that may be important to you you should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement we have not authorized anyone to provide you with different information we are not making an offer of these securities in any state where the offer is not permitted you should not assume that the information in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents    myokardia inc nasdaqmyokhistorical stock chart  year  from jul  to jul  myokardia inc nasdaqmyokintraday stock chart today  friday  july  latest myok messages view more posts remove from favorites add to favorites  message board see more message board posts your recent history lse gkp gulf keyst lse qpp quindell ftse ukx ftse  lse iof iofina fx gbpusd uk sterlin stocks youve viewed will appear in this box letting you easily return to quotes youve seen previouslyregister now to create your own custom streaming stock watchlist nyse amex and asx quotes are delayed by at least  minutesall other quotes are delayed by at least  minutes unless otherwise stated trv gp ii llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors trv gp ii llc check out list of companies and businesses related to trv gp ii llc find out trv gp ii llc address and contact details view other people related to trv gp ii llc  coworkers colleagues companions etc address  newbury street rd floor boston  ma companies related to trv gp ii llc cikcompany namepositioncompany addressmyokardia inc allerton avenue south san francisco blueprint medicines corp sidney street suite  cambridge sage therapeutics inc first street cambridge global blood therapeutics inc east jamie court suite  south san francisco jounce therapeutics inc memorial drive cambridge  trv gp ii llc on the web persons related to trv gp ii llc  myokardia incnamepositioncitysunil agarwaldirector novatojake bauersee remarks south san franciscosteven chansee remarks south san franciscohomcy charlessan franciscohomcy charlessan franciscohomcy charlessan franciscohomcy charlessouth san franciscohomcy charlessouth san franciscomary b cranstondirector san franciscojonathan c foxchief medical officer south san franciscoanastasios gianakakospresident and ceo mountain viewcharles j homcydirector south san franciscobowdish katherinesouth san franciscobowdish katherinesouth san franciscostarr kevinsan franciscostarr kevinsouth san franciscostarr kevinsouth san franciscojoseph lambingsee remarks south san franciscojune leechief operating officer south san franciscomark j levincambridgeperry marksouth san franciscoperry marksouth san franciscorobert scott mcdowellsee remarks south san franciscodavid p meekerdirector danburymark l perrydirector sunnyvalekimberly j popovitsdirector redwood citysanofiaventis owner parismarc semigranchief medical officer south san franciscokevin p starrdirector cambridgegianakakos tassossouth san franciscogianakakos tassossouth san franciscorobert i teppercambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lpbostoneric topoldirector san diegotrv gp iii llcbostonwendy l yarnodirector st paulpersons related to trv gp ii llc  blueprint medicines corpnamepositioncityjeffrey w albersceo and president cambridgeborisy alexiscambridgeborisy alexiscambridgeanthony l boralchief medical officer cambridgealexis borisydirector bostonbellon christinecambridgebellon christinecambridgelengauer christophcambridgelengauer christophcambridgelonnel coatsdirector the woodlandslynch danielcambridgelynch danielcambridgeschenkein davidcambridgeschenkein davidcambridgegeorge demetridirector cambridgemarion dorschchief scientific officer cambridgefmr corp owner bostonmark alan goldbergdirector needhamkate havilandchief business officer cambridgealbers jeffreycambridgekyle d kuvalankacambridgekuvalanka kylecambridgekuvalanka kylecambridgemichael landsittelpfo and pao cambridgechristoph lengauerchief scientific officer cambridgemark j levin owner cambridgenicholas lydondirector cambridgedaniel lynchdirector tracey l mccainevp and chief legal officer cambridgelydon nicholascambridgelydon nickcambridgecharles a rowland jrdirector chadds fordlynn seelydirector san franciscokevin p starr owner cambridgeknight stephencambridgeknight stephencambridgerobert i teppercambridgeschroeder thilocambridgeschroeder thilocambridgethird rock ventures gp ii lpbostonthird rock ventures ii lp owner bostonpersons related to trv gp ii llc  sage therapeutics incnamepositioncitythomas andersonsee remarks cambridgearch venture fund vii lp owner chicagoarch venture partners vii lpchicagoarch venture partners vii llcchicagoclinton bybeechicagoclinton bybeechicagomichael cloonanchief business officer cambridgemichael f cola waynemichael f coladirector cambridgeanne marie cooksee remarks cambridgekeith crandellchicagokeith crandellchicagojames m frates cambridgejames m fratesdirector cambridgegeno j germano madisonkimi iguchicfo  treasurer foxboroughkimi iguchicfo secretary and treasurer cambridgejeffrey m jonaspresident  ceo carlsbadjeffrey m jonaspresident and ceo cambridgestephen kaneschief medical officer cambridgestephen kaneschief medical officer cambridgestarr kevincambridgemark j levincambridgemark j levinbostonmark j levinbostonrobert nelsendirector robert nelsendirector chicagorobert nelsendirector chicagosteven m pauldirector steven m pauldirector cambridgehoward h pien emeryvillehoward h piencambridgealbert robichaudchief scientific officer cambridgekevin p starrdirector cambridgekevin p starrdirector cambridgekevin p starrdirector bostonpaul stevencambridgerobert i teppercambridgerobert i tepperbostonrobert i tepperbostonthird rock ventures gp ii lpbostonthird rock ventures ii lp owner bostonthird rock ventures ii lp owner bostonpersons related to trv gp ii llc  global blood therapeutics incnamepositioncitymichael w bonneydirector lexingtonwillie l jr browndirector south san franciscohomcy md charlessouth san franciscojung choisee remarks south san franciscojeffrey s farrowchief financial officer south san franciscocharles j homcydirector south san franciscoschembri johnsouth san franciscostarr kevinsouth san franciscomark j levincambridgeted w loveceo and president sunnyvalescott w morrisondirector south san franciscodeval l patrickdirector mark l perrydirector sunnyvaleglenn piercedirector alamedaphilip a pizzodirector memphispeter radovichsee remarks south san franciscoeleanor ramoschief medical officer seattlejohn schembrisee remarks san franciscohing shamsee remarks south san franciscokevin p starr owner cambridgetricia borga suvarichief legal officer palo altolove tedsouth san franciscorobert i tepper owner cambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lp owner bostontrv gp iii llcbostonpersons related to trv gp ii llc  jounce therapeutics incnamepositioncitybarry annacambridgepfeffer carycambridgecelgene corp desummitcelgene switzerland llc owner pembrokekimberlee c drapkinlexingtonbarbara gayle duncansomersethadley harbor master investors cayman lp owner bostonjohn duncan higgonsdirector cambridgerobert kamencambridgeperry a karsendirector rockvilledrapkin kimcambridgemark j levincambridgerichard ca murrayfremontcary pfeffercambridgemurray richardcambridgekamen robertcambridgetepper robertcambridgekevin p starrcambridgerobert i tepperdirector cambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lpbostonelizabeth trehucambridgetrv gp iii llcboston trv gp iii llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors trv gp iii llc check out list of companies and businesses related to trv gp iii llc find out trv gp iii llc address and contact details view other people related to trv gp iii llc  coworkers colleagues companions etc address  newbury street boston  ma companies related to trv gp iii llc cikcompany namepositioncompany addressmyokardia inc allerton avenue south san francisco global blood therapeutics inc east jamie court suite  south san francisco voyager therapeutics inc sidney street cambridge jounce therapeutics inc memorial drive cambridge editas medicine inc hurley st cambridge  trv gp iii llc on the web persons related to trv gp iii llc  myokardia incnamepositioncitysunil agarwaldirector novatojake bauersee remarks south san franciscosteven chansee remarks south san franciscohomcy charlessan franciscohomcy charlessan franciscohomcy charlessan franciscohomcy charlessouth san franciscohomcy charlessouth san franciscomary b cranstondirector san franciscojonathan c foxchief medical officer south san franciscoanastasios gianakakospresident and ceo mountain viewcharles j homcydirector south san franciscobowdish katherinesouth san franciscobowdish katherinesouth san franciscostarr kevinsan franciscostarr kevinsouth san franciscostarr kevinsouth san franciscojoseph lambingsee remarks south san franciscojune leechief operating officer south san franciscomark j levincambridgeperry marksouth san franciscoperry marksouth san franciscorobert scott mcdowellsee remarks south san franciscodavid p meekerdirector danburymark l perrydirector sunnyvalekimberly j popovitsdirector redwood citysanofiaventis owner parismarc semigranchief medical officer south san franciscokevin p starrdirector cambridgegianakakos tassossouth san franciscogianakakos tassossouth san franciscorobert i teppercambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lpbostoneric topoldirector san diegotrv gp ii llcbostonwendy l yarnodirector st paulpersons related to trv gp iii llc  global blood therapeutics incnamepositioncitymichael w bonneydirector lexingtonwillie l jr browndirector south san franciscohomcy md charlessouth san franciscojung choisee remarks south san franciscojeffrey s farrowchief financial officer south san franciscocharles j homcydirector south san franciscoschembri johnsouth san franciscostarr kevinsouth san franciscomark j levincambridgeted w loveceo and president sunnyvalescott w morrisondirector south san franciscodeval l patrickdirector mark l perrydirector sunnyvaleglenn piercedirector alamedaphilip a pizzodirector memphispeter radovichsee remarks south san franciscoeleanor ramoschief medical officer seattlejohn schembrisee remarks san franciscohing shamsee remarks south san franciscokevin p starr owner cambridgetricia borga suvarichief legal officer palo altolove tedsouth san franciscorobert i tepper owner cambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lp owner bostontrv gp ii llcbostonpersons related to trv gp iii llc  voyager therapeutics incnamepositioncitywendy l dixondirector princetonjames a geraghtydirector framinghamjeff goaterchief financial officer cambridgehadley harbor master investors cayman lp owner bostonjane hendersonsr vp  cfo watertownmichael j higginsdirector cambridgesteven hymandirector cambridgegeraghty jamescambridgeperry a karsendirector rockvillemark j levindirector cambridgelevin markcambridgebloom mitchellbostonsteven m paulpresident and ceo glenn piercedirector alamedabernard ravinacambridgedinah phd sahcambridgesanofiaventis pariskevin p starrcambridgepaul stevencambridgerobert i teppercambridgethird rock ventures gp iii lpbostonthird rock ventures iii lp owner bostonpersons related to trv gp iii llc  jounce therapeutics incnamepositioncitybarry annacambridgepfeffer carycambridgecelgene corp desummitcelgene switzerland llc owner pembrokekimberlee c drapkinlexingtonbarbara gayle duncansomersethadley harbor master investors cayman lp owner bostonjohn duncan higgonsdirector cambridgerobert kamencambridgeperry a karsendirector rockvilledrapkin kimcambridgemark j levincambridgerichard ca murrayfremontcary pfeffercambridgemurray richardcambridgekamen robertcambridgetepper robertcambridgekevin p starrcambridgerobert i tepperdirector cambridgethird rock ventures gp ii lpbostonthird rock ventures gp iii lpbostonthird rock ventures ii lp owner bostonthird rock ventures iii lpbostonelizabeth trehucambridgetrv gp ii llcbostonpersons related to trv gp iii llc  editas medicine incnamepositioncitynoubar afeyanlexingtoncharles albrightchief scientific officer cambridgeglucksmann alexandracambridgeborisy alexiscambrigehack andrewcambridgekevin bittermandirector walthambng llc owner seattlenikolic boriscambridgealexis borisydirector bostonkatrine bosleypresident and ceo cambridgegeorge churchst louisdouglas g coledirector cambridgegerald frank coxchief medical officer cambridgedeerfield healthcare innovations fund lpnew yorkmanagement co ny deerfieldmgmt hif lp deerfieldnew yorkdeerfield mgmt iii lpnew yorkdeerfield private design fund iii lpnew yorkcole douglascambridgflagship ventures fund iv general partner llccambridgeflagship ventures fund iv lp owner cambridgeflagship ventures fund ivrx lpcambridgejames e flynn owner new yorkalexandra glucksmannchief operating officer cambridgeandrew a f hackchief financial officer cambridgeole andreas halvorsengreenwichandrew hirschdirector cambridgej keith joungcambridgeedwin m kania jrcambridgebosley katrinecambridgebitterman kevincambridgemark j levincambridgedavid r liucambridgejohn mendleindirector toronto canada mjhboris nikolicdirector cambridgedavid c ottgreenwichpolaris venture management co vi llc owner walthampolaris venture partners founders fund vi lpwalthampolaris venture partners vi lpwalthamkevin p starr owner cambridgedaniel s sundheimgreenwichrobert i teppercambridgethird rock ventures gp iii lpbostonthird rock ventures iii lp owner bostonakshay vaishnawdirector cambridgevge iii portfolio ltdgreenwichmyer viccambridgeviking global equities ii lpgreenwichviking global equities lpgreenwichviking global investors lp owner greenwichviking global opportunities gp llcgreenwichviking global opportunities illiquid investments submaster lpgreenwichviking global opportunities portfolio gp llcgreenwichviking global performance llc owner greenwichviking long fund gp llcgreenwichviking long fund master ltdgreenwichfeng zhangcambridge trv gp ii llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active trv gp ii llc • boston ma how do i update this listing trv gp ii is based out of boston summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from trv gp ii llc enter your email address below and choose submit your email cancel contact info trv gp ii llc third rock ventures boston ma     business phone  sec sic codepharmaceutical preparations recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free shareholder rights agreement shareholder rights contracts  free legal documents page  of   you are here agreements  shareholder rights agreement search documents  browse documents site search agreements  contracts document title entire documentoptional governing lawoptional allalabamaalaskaarizonaarkansascaliforniacoloradoconnecticutdelawareflorida georgiahawaiiidahoillinoisindianaiowakansaskentuckylouisianamainemaryland massachusettsmichiganminnesotamississippimissourimontananebraskanevada new hampshirenew jerseynew mexiconew yorknorth carolinanorth dakotaohiooklahoma oregonpennsylvaniarhode islandsouth carolinasouth dakotatennesseetexasutah vermontvirginiawashingtonwest virginiawisconsinwyoming try our advanced search  clauses search contract clauses  browse contract clause library shareholder rights agreements these shareholder rights agreements are actual legal documents drafted by top law firms for their clients use them for competitive intelligence drafting documents or to get information about transactions within a particular industry or sector we have millions of legal documents and clauses that you can search for free  cloudera inc amended and restated investor rights agreementparties cloudera inc  accel growth fund ii associates llc  accel growth fund investors  llc  accel investors  llc  accel partners  accel x associates llc  cloudera inc  greylock management corporation  greylock xii gp llc  greylock xii limited partnership  greylock xii principals llc  greylock xiia limited partnership  intel capital corporation  intel corporation law firm perkins coiefenwick west document date  governing lawdelaware  investor rights agreementparties akcea therapeutics inc  ackea therapeutics inc  akcea therapeutics inc  isis pharmaceuticals inc document date  governing lawdelaware  exparties tesla inc  tesla inc document date   investor rights agreementparties veritone inc   media holdings llc   media holdings llc  ad pepper media international nv  banta investment partners llc  brand affinity technologies inc  checketts partners investment gp llc  fulcrum venture capital iii llc  miramar digital associates llc  miramar venture associates ii llc  newport coast investments llc  radio dial llc  rimlight llc  steel holdings llc  veritone inc  vif i llc  woodland company llc law firm dla pipervedder price document date  governing lawcalifornia  investor rights agreement dated as of march   by and amongparties connecture inc  chrysalis partners ii llc  chrysalis ventures ii lp  connecture inc  francisco partners gp iv management limited  francisco partners iv lp  francisco partners iva lp law firm dla piperkirkland ellis document date  governing lawdelaware  fifth amended and restated investors rights agreementparties yext inc  g leonard baker jr and mary anne baker co  insight venture associates viii ltd  institutional venture management xi llc  institutional venture management xii llc  institutional venture partners xi gmbh co  leland stanford junior university  managing limited  marker ii gp ltd  michael l speiser and mary elizabeth speiser co  naar family trust  samuel j pullara iii and lucia choi pullara co  tench coxe and simone otus coxe co  wells fargo bank na  wgi group llc  white family trust  yext inc  yin family trust law firm lowenstein sandler document date  governing lawnew york  okta inc amended and restated investors rights agreement july  parties okta inc  ah equity partners i llc  ah equity partners iv parallel llc  altimeter private general partner llc  glynn capital management llc  glynn management iii llc  glynn management iv llc  greylock management corporation  greylock xiii gp llc  greylock xiii limited partnership  greylock xiii principals llc  greylock xiiia limited partnership  h barton asset management llc  h barton coinvest fund ii llc  khosla ventures associates iv llc  klh associates  okta inc  sc us ttgp ltd  sc us gf v holdings ltd document date  governing lawcalifornia  investor rights agreement dated as of december  parties arch capital group ltd  american international group inc  arch capital group ltd  company  company law firm cahill gordonsullivan cromwell document date  governing lawnew york  alteryx inc second amended and restated investors rights agreement september  parties alteryx inc  alteryx inc  fish foundation  insight venture management llc  meritech capital affiliates v lp  meritech capital partners v lp  sapphire ventures fund i lp toba capital fund ii llc document date  governing lawdelaware  harvest natural resources adopts shareholder rights plan to preserve valuable net operating lossesparties harvest natural resources inc  harvest natural resources inc document date   mulesoft inc sixth amended and restated investors rights agreement may  parties mulesoft inc  adage capital advisors llc  adage capital partners gp llc  bay management company xi llc  cisco systems inc  hummer winblad equity partners v llc  hummer winblad equity partners vi llc  jon avina wilson sonsini goodrich rosati pc  lightspeed ultimate general partner select ltd  meritech capital associates iv llc  morgenthaler management partners  nea  gp ltd  nea  gp llc  nea ventures  limited partnership  sands capital private growth fundgp llc  sapphire ventures gpe i llc  servicenow inc law firm wilson sonsini document date  governing lawcalifornia  investor rights agreementparties gold torrent inc  crh mezzanine pte ltd  gold torrent inc  kane kessler pc law firm dorsey whitney document date  governing lawnew york  legacy education alliance inc adopts shareholder rights planparties legacy education alliance inc  legacy education alliance inc document date   amendment no  to shareholder rights agreementparties neurometrix inc  american stock transfer trust company llc  neurometrix inc document date  governing lawdelaware  first amendment to investor rights and standstill agreementparties legg mason inc  legg mason inc  shanda asset management investment limited document date  governing lawnew york  investor rights agreement dated as of january   among china jojo drugstores inc careretail holdings limited and certain other parties named hereinparties china jojo drugstores inc  careretail holdings limited  china jojo drugstores inc  hangzhou jiuzhou grand pharmacy chain co ltd  super marvel limited law firm skadden arps document date  governing lawnew york  amended and restated investors rights agreementparties jounce therapeutics inc  foresite capital management ii llc  jounce therapeutics inc  omega fund iv gp manager ltd  pharmstandard international sa  redmile capital offshore fund ii ltd  redmile capital offshore fund ltd  redmile special opportunities fund ltd  trv gp ii llc  trv gp iii llc law firm goodwin procterwilmer cutlermorgan lewis document date  governing lawmassachusetts  investor rights agreementparties braeburn pharmaceuticals inc  apple tree partners iv lp  atp iii gp ltd  braeburn pharmaceuticals inc document date  governing lawdelaware  amendment no  to shareholder rights agreementparties neurometrix inc  american stock transfer trust company llc  neurometrix inc document date  governing lawdelaware  appdynamics inc sixth amended and restated investors rights agreement november  parties appdynamics inc  adage capital advisors llc  adage capital partners gp llc  altimeter general partner llc  appdynamics inc  greylock management corporation  greylock xii gp llc  greylock xii limited partnership  greylock xii principals llc  greylock xiia limited partnership  lightspeed ultimate general partner vii ltd law firm fenwick westwilson sonsini document date  governing lawcalifornia  freds pharmacy unanimously adopts shareholder rights planparties freds inc  freds inc law firm baker donelsonvinson elkins document date   investor rights agreementparties barfresh food group inc  barfresh food group inc  rd capital holdings pty ltd  sidra pty limited document date   shareholders and registration rights agreementparties klr energy acquisition corp  anchorage capital group llc  klr energy acquisition corp  klr energy sponsor llc  rosehill operating company llc  rosemore inc  tema oil and gas company law firm milbank tweedvinson elkins document date  governing lawdelaware  investor rights and standstill agreementparties legg mason inc law firm wachtell liptondavis polk document date  governing lawnew york  dorian lpg ltd adopts shareholder rights planparties dorian lpg ltd  dorian lpg ltd document date   investor rights agreement by and among mammoth energy services inc and gulfport energy corporation dated as of october  parties mammoth energy services inc  gulfport energy corporation  mammoth energy services inc document date  governing lawdelaware  ichor holdings ltd investor rights agreement march   table of contentsparties ichor holdings ltd  francisco partners gp iii management cayman limited  ichor holdings ltd  ichor investment holdings llc law firm kirkland ellis document date  governing lawdelaware  amendment no  to amended and restated investors rights agreementparties angies list inc  angies list inc  tri investments llc document date   investor rights agreementparties blackboxstocks inc  blackboxstocks inc document date  governing lawtexas  investor rights agreementparties rice energy inc  rice energy inc  rice energy operating llc law firm latham watkins document date  governing lawnew york  investor rights agreement oaktree organics lp and oaktree huntington investment fund ii lp and sunopta inc and sunopta foods incparties sunopta inc  oaktree huntington investment fund ii lp  oaktree organics lp  sunopta foods inc  sunopta inc law firm kirkland ellis document date  governing lawdelaware  investors rights agreementparties horizon global corp  horizon global corporation  parcom deutschland i gmbh co  teijs holding bv law firm jones day document date  governing lawnew york  amended and restated investors rights agreementparties ra pharmaceuticals inc  amgen ventures llc  blackwell parnters llc  limulus ii llc  limulus venture partners ii limited partnership  lsv associates llc  morgenthaler management partners ix llc  nea  gp ltd  nea ventures  limited partnership  novartis bioventures ltd  ra capital management llc  ra pharmaceuticals inc  rock springs gp llc law firm dla pipergoodwin proctermintz levin document date  governing lawmassachusetts  investor rights agreementparties myovant sciences ltd  head global transactions risk management  roivant endocrinology ltd  roivant sciences ltd  takeda pharmaceuticals international ag document date  governing lawdelaware  quantenna communications inc amended and restated investors rights agreementparties quantenna communications inc  arthur f schneiderman esq wilson sonsini goodrich roast pc  centerview capital technology ltd  china walden venture investments ii gp ltd  dag ventures iva llc  dag ventures management iv llc  eastward investors llc  grazia beteilingungen gmbh co  hatteras vc coinvestment fund ii llc  management pty limited  managing limited  open joint stock company  quantenna communications inc  sc gf v tt ltd  sc us gf v holdings ltd  sc xi management llc  sequoia technology partners  sigma management  llc  southern cross venture partners  swisscom ag  telefonica digital venture  uniquest corporation  venrock management iv llc  vivint wireless inc  wrv gp ii llc law firm wilson sonsini document date  governing lawdelaware  for immediate releaseparties sunlink health systems inc  sunlink health systems inc document date   shareholder rights protection agreementparties pier  imports incde  computershare inc  pier  imports inc document date  governing lawnew york  news release pier  imports inc adopts shortterm shareholder rights protection agreementparties pier  imports incde  pier  imports inc law firm skadden arpsalston bird document date   irhythm technologies inc amended and restated investors rights agreement may  parties irhythm technologies inc  genesis vc partners xi llc  genesis vc partners xii llc  irhythm technologies inc  kaiser permanente ventures llc  leland stanford junior university  new leaf venture management ii llc  new leaf venture partners llc  nvp associates llc  permanente federation llc  revelation llc  st jude medical inc  stanford management company  synergy venture partners llc  ws investment company llc law firm wilson sonsini document date  governing lawcalifornia  amended and restated shareholder rights plan agreementparties open text corp  computershare investor services inc  open text corporation  professional client services document date   fourth amended and restated investors rights agreementparties obalon therapeutics inc  axon managers llc  axon ventures viii llc  bader sultan bros co  black diamond ventures  llc  ferayorni family trust  interwest management partners x llc  lucas venture group xvi llc  lvg gp iv llc  obalon therapeutics inc  okapi venture partners ii llc  okapi venture partners llc  one palmer square associates vii llc document date  governing lawcalifornia  press releaseparties magnachip semiconductor corp  about magnachip semiconductor corporation document date   fulgent therapeutics llc investors rights agreement dated as of may  parties fulgent genetics inc  fulgent therapeutics llc  xi long usa inc law firm morrison foerster document date  governing lawcalifornia  amendment no  to shareholder rights agreementparties insulet corp  computershare trust company na  insulet corporation document date  industry medical equipment and supplies sector healthcare governing lawdelaware  apptio inc amendment to amended and restated investors rights agreementparties apptio inc  apptio inc document date  governing lawdelaware  apptio inc amended and restated investors rights agreement may   table of contentsparties apptio inc  apptio inc  wilson sonsini goodrich rosati professional corporation law firm dla pipergoodwin procterproskauer rosewilson sonsini document date  governing lawdelaware  everbridge  i nc third amended and restated investor rights agreementparties everbridge inc  brmr llc  calvert capital v llc  dolphin equity partners hi llc  doughty hanson co  everbridge inc  officers nominees limited  pmc financial services group llc law firm nixon peabody document date  governing lawdelaware  fourth amended and restated investor rights agreementparties thar pharmaceuticals inc  ashaway limited  breedlove family limited  dfb management llc  empire advisors llc  thar pharmaceuticals inc document date  governing lawdelaware  shareholders voting rights proxy agreementparties dswiss inc  ds asia co ltd  dswiss hk limited document date   shareholder voting rights proxy agreementparties dswiss inc  dswiss hk limited document date  browse by statego directly to a specific page of results